Skip to Main Content

An unusual battle between two small companies over the market for a rare disease drug has now spread to Canada, where Catalyst Pharmaceuticals (CPRX) has gone to court in hopes of blocking a rival medicine sold by Jacobus Pharmaceuticals, a small, family-run company, from reaching patients.

At issue is the small, but potentially lucrative market to treat people with a rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS. Last month, Health Canada endorsed the use of the Jacobus drug, but Catalyst claims the decision was “incorrect and unreasonable” because the regulator should not have referenced its drug in a compliance notice due to data protection.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.